Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,620 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors.
Fukuokaya W, Kimura T, Komura K, Uchimoto T, Nishimura K, Yanagisawa T, Imai Y, Iwatani K, Ito K, Urabe F, Tsuzuki S, Kimura S, Terada N, Mukai S, Oyama Y, Abe H, Kamoto T, Azuma H, Miki J, Egawa S. Fukuokaya W, et al. Among authors: imai y. Urol Oncol. 2022 Jul;40(7):346.e1-346.e8. doi: 10.1016/j.urolonc.2022.02.020. Epub 2022 Mar 26. Urol Oncol. 2022. PMID: 35346571
Site-Specific Differences of Eligibility for Adjuvant Immunotherapy Among Urothelial Carcinoma Patients Treated With Radical Surgery: Results From a Multicenter Cohort Study.
Narita C, Urabe F, Fukuokaya W, Iwatani K, Imai Y, Yasue K, Mori K, Aikawa K, Yanagisawa T, Kimura S, Tashiro K, Tsuzuki S, Yamada Y, Yuen SKK, Teoh JY, Shimomura T, Yamada H, Furuta A, Miki J, Kimura T; JIKEI-YAYOI Collaborative Group. Narita C, et al. Among authors: imai y. Clin Genitourin Cancer. 2024 Jun;22(3):102082. doi: 10.1016/j.clgc.2024.102082. Epub 2024 Mar 21. Clin Genitourin Cancer. 2024. PMID: 38641443
Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study.
Urabe F, Muramoto K, Yanagisawa T, Fukuokaya W, Mori K, Tashiro K, Katsumi K, Takahashi H, Yoshihara K, Miyajima K, Imai Y, Iwatani K, Kayano S, Igarashi T, Murakami M, Tsuzuki S, Shimomura T, Yamada H, Miki J, Kimura T; JIKEI‐YAYOI Collaborative Group. Urabe F, et al. Among authors: imai y. Int J Urol. 2024 Nov;31(11):1248-1255. doi: 10.1111/iju.15546. Epub 2024 Jul 19. Int J Urol. 2024. PMID: 39031448
Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter study.
Urabe F, Imai Y, Goto Y, Tashiro K, Hashimoto M, Yoshihara K, Yamamoto S, Hara S, Miyajima K, Fukuokaya W, Enei Y, Iwatani K, Kayano S, Igarashi T, Aikawa K, Yanagisawa T, Kimura S, Tsuzuki S, Murakami M, Hata K, Shimomura T, Yamada H, Miki J, Kimura T. Urabe F, et al. Among authors: imai y. Jpn J Clin Oncol. 2024 Nov 2;54(11):1208-1213. doi: 10.1093/jjco/hyae098. Jpn J Clin Oncol. 2024. PMID: 39037966
A case of pagetoid spread of urothelial carcinoma with notable reduction achieved through enfortumab vedotin, resulting in complete surgical resection.
Tokuoka K, Muramoto K, Sakanaka K, Yoshihara K, Yamamoto S, Imai Y, Iwatani K, Tashiro K, Murakami M, Harada T, Hayashimoto T, Umemori M, Kimura T, Shimomura T, Urabe F. Tokuoka K, et al. Among authors: imai y. Int Cancer Conf J. 2024 Aug 31;13(4):510-514. doi: 10.1007/s13691-024-00720-3. eCollection 2024 Oct. Int Cancer Conf J. 2024. PMID: 39398921
4,620 results